INNOVATE (VATE) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
11 Jun, 2026Opening remarks and agenda
Meeting called to order with board members and executive officers introduced.
Attendees welcomed and informed about the Q&A session following the meeting.
Agenda and rules of conduct made available on the meeting site.
Board and executive committee updates
Board members present included Avi Glazer, Warren Gfeller, Brian Goldstein, and Amy Wilkinson.
Interim CEO Paul Voigt and CFO Michael Sena were introduced.
Shareholder proposals
Four proposals presented: election of directors, advisory vote on executive compensation, amendment to equity award plan, and ratification of accounting firm.
No other nominations for directors were submitted.
Partial view of Summaries dataset, powered by Quartr API
Latest events from INNOVATE
- Major asset sales will eliminate most revenue, with proceeds used for debt repayment, not shareholders.VATE
Registration filing - Q2 2026 revenue jumped 74.2% to $421.6M, with net income of $10.4M and major asset sales underway.VATE
Q2 2026 - Revenue up 33% to $364.8M, net loss narrowed, but debt maturities pose going concern risk.VATE
Q1 2026 - Annual meeting to vote on directors, compensation, equity plan, and auditor ratification.VATE
Proxy filing - Board recommends FOR all proposals, with focus on growth, governance, and executive alignment.VATE
Proxy filing - Q4 2025 revenue up 61.7% to $382.7M, with strong Infrastructure growth and narrowing net loss.VATE
Q4 2025 - Q3 revenue dropped 35.5% to $242.2M; growth in Life Sciences and Spectrum, but going concern risk remains.VATE
Q3 2024 - Q2 net income rose to $14.4M as margins improved and Life Sciences posted record sales.VATE
Q2 2024 - Revenue declined, but Life Sciences and Spectrum grew; debt reduced and backlog remains strong.VATE
Q4 2024